| Code | Name | Last | Change(%) | P/E | Yield (%) | P/E Range | ||
| STOK | Stoke Therapeutics |  | 31.54 | -6.66% | 49.51 | -- |  | |
| BBOT | BridgeBio Oncology Therapeutics Inc | | 11.415 | -3.91% | 48.16 | -- | | |
| CORT | Corcept Therapeutics | | 39.5801 | -2.75% | 46.95 | -- | | |
| LENZ | LENZ Therapeutics | | 14.71 | -5.28% | 45.35 | 32.39 | | |
| CSBR | Champions Oncology | | 6.62 | -7.18% | 41.95 | 1.45 | | |
| KRYS | Krystal Biotech | | 264.55 | -5.37% | 41.91 | -- | | |
| ARGX | argenx SE | | 849.845 | -0.22% | 36.43 | -- | | |
| XOMA | XOMA Royalty Corporation | | 26.5 | -1.74% | 35.96 | 2.03 | | |
| TBPH | Theravance Biopharma |  | 20.16 | +0.85% | 35.07 | -- | | |
| PLX | Protalix BioTherapeutics | | 2.9 | +6.23% | 35 | -- | | |
| VRTX | Vertex Pharmaceuticals | | 472.945 | +1.58% | 32.83 | -- | | |
| IMTX | Immatics NV | | 9.315 | -6.38% | 29.95 | -- | | |
| AUPH | Aurinia Pharmaceuticals | | 14.655 | -3.65% | 27.16 | -- | | |
| CTNM | Contineum Therapeutics | | 14.33 | -5.79% | 26.3 | -- | | |
| SMMT | Summit Therapeutics | | 14.28 | -2.12% | 25.11 | -- | | |
| RPRX | Royalty Pharma plc | | 43.61 | +1.49% | 24.55 | 2.56 | | |
| NAGE | Niagen Bioscience Inc | | 5.56 | -2.03% | 23.65 | -- | | |
| BMRN | BioMarin Pharmaceutical | | 57.385 | -0.39% | 21.42 | -- | | |
| RAPP | Rapport Therapeutics Inc. | | 26.25 | -4.34% | 21.13 | -- | | |
| ICCC | ImmuCell Corp | | 5.8 | -0.68% | 20.86 | -- | | |
 | 1Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)：2026/02/04 14:02 EDT |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |